Listed by the USPTO as SU-TOBON, QIWEN NMN
Tech Center 1600 • Art Units: 1600 1636 1642
This examiner grants 67% of resolved cases
SU-TOBON, QIWEN NMN works in tech center 1600 and art unit 1600. The record includes 6 resolved cases, an allowance rate of 66.7%, an interview lift of 66.7%, and a median of 1212 days to allowance. The limited number of resolved cases makes the figures preliminary, but the record shows both a majority allowance outcome and a substantial measured interview association.
The listed companies are The Johns Hopkins University, University of Florida Research Foundation Inc., and Massachusetts Institute of Technology. Knobbe, Martens, Olson & Bear, LLP, MARSHALL, GERSTEIN & BORUN LLP, and ARRIGO, LEE, GUTTMAN & MOUTA-BELLUM LLP are the listed firms. File-specific review is important given the small record.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 16972740 | AAV CARDIAC GENE THERAPY FOR CARDIOMYOPATHY | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 18032868 | REPROGRAMMABLE ISCB NUCLEASES AND USES THEREOF | Final Rejection | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 18262792 | PREVENTIVE OR THERAPEUTIC AGENT FOR BENIGN ADULT FAMILIAL MYOCLONIC EPILEPSY | Final Rejection | RIKEN |
| 18312196 | ANASTASIS BIOSENSOR CASPASE TRACKER | Non-Final OA | THE JOHNS HOPKINS UNIVERSITY |
| 16226714 | DNA METHYLATION MARKERS FOR METASTATIC PROSTATE CANCER | Non-Final OA | THE JOHNS HOPKINS UNIVERSITY |
| 18287861 | Supercharged Biovesicles and Methods of Use Thereof | Non-Final OA | The General Hospital Corporation |
| 17800417 | COMPOSITIONS AND METHODS FOR IDENTIFYING HOST CELL TARGET PROTEINS FOR TREATING RNA VIRUS INFECTIONS | Non-Final OA | The Regents of the University of California |
| 17849132 | METHODS AND COMPOSITIONS FOR INHIBITING CORONAVIRAL REPLICATION | Final Rejection | California Institute of Technology |
| 17928028 | MODULAR PLATFORM FOR PROGRAMMABLE SPATIOTEMPORAL BIOMOLECULE CLUSTERING WITH APPLICATIONS INCLUDING ENHANCED METABOLIC YIELD | Non-Final OA | The Trustees of Princeton University |
| 18330563 | SUMO Targeting Morpholinos as both Enhancers of Anti-Cancer Effects of Chemotherapeutic Treatments and Preventative Agents Against the Establishment of Chemoresistance | Final Rejection | Board of Regents, The University of Texas System |
| 18546378 | SITE-SPECIFIC GENOME MODIFICATION TECHNOLOGY | Non-Final OA | North Carolina State University |
| 18287682 | PRODUCTS AND METHODS FOR INDUCING EXON 2 SKIPPING OF THE DMD GENE IN TREATING MUSCULAR DYSTROPHY | Non-Final OA | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy66.7% of resolved applications examined by Qiwen Nmn Su-Tobon were allowed (6 resolved cases), compared with 37.3% across Art Unit 1600 over the last five years.
This examiner's interview lift is +66.7 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Qiwen Nmn Su-Tobon took 1,212 days on average from filing to allowance.
Qiwen Nmn Su-Tobon examines applications in Art Unit 1600 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
